Ditchcarbon
  • Customers
  1. Organizations
  2. Hikma Pharmaceuticals
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 9 days ago

Hikma Pharmaceuticals

Company website

Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.

DitchCarbon Score

How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

67

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Hikma Pharmaceuticals's score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Hikma Pharmaceuticals's reported carbon emissions

In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 1,000,000,000 kg CO2e, comprising 37,625,000 kg CO2e from Scope 1, 85,682,000 kg CO2e from Scope 2, and a significant 860,710,000 kg CO2e from Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, including all relevant scopes. Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment is part of their broader strategy to achieve net zero emissions by 2050. The company has made progress, reporting a 4% reduction in emissions from direct fuel usage and electricity consumption since 2017. In 2023, the company reported total emissions of approximately 837,000,000 kg CO2e, with Scope 1 emissions at 43,830,000 kg CO2e and Scope 2 emissions at 79,897,000 kg CO2e. The trend indicates a focus on improving sustainability practices and reducing carbon footprints across their operations. Hikma's emissions data is independently reported and does not cascade from any parent organization, ensuring transparency in their climate commitments. The company continues to align its operations with industry standards for climate action, demonstrating a proactive stance in addressing climate change.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20132014201520172018201920202021202220232024
Scope 1
16,817,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
49,779,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Hikma Pharmaceuticals's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Hikma Pharmaceuticals is in GB, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Hikma Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Almirall

ES
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Hospira

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Bausch & Lomb Incorporated

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Adcock Ingram Holdings Limited

ZA
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

RECORDATI

LU
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Auro Medics Pharma Llc

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250807.5
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy